Semaglutide is a 31-amino-acid synthetic peptide and a GLP-1 receptor agonist developed by Novo Nordisk. It is FDA-approved as Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral form for type-2 diabetes).

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Popular compounds

Research resources

Certificates of Analysis

Semaglutide: A Research Guide to the GLP-1 Single Agonist

Q: How long is semaglutide’s half-life?

Approximately 165 hours (about 7 days) for the injectable form, which supports once-weekly dosing. The long half-life comes from a C18 fatty di-acid moiety that drives reversible albumin binding.

In short: Semaglutide is a 31-amino-acid synthetic peptide and a selective GLP-1 receptor agonist from Novo Nordisk. Licensed medicines include Ozempic, Wegovy and Rybelsus. The STEP programme reported about 14.9% mean weight reduction over 68 weeks in the studied population. New-U lists research-grade lyophilised semaglutide with per-batch CoA, research use only.

Key facts

31-amino-acid GLP-1 analogue; half-life about 7 days (albumin binding via C18 fatty di-acid).

Single GLP-1 agonist; no GIP or glucagon receptor activity.

Evidence base: SUSTAIN (diabetes), STEP (weight management), SELECT (cardiovascular outcomes).

Licensed medicines and research-grade reference peptide are separate supply categories.

New-U sells the research reagent only: no human-use claims or dosing guidance.

Semaglutide turned “GLP-1” into a household acronym. It draws roughly 550,000 monthly Google searches in the United States alone . It sits just behind tirzepatide in the incretin search landscape. Head-to-head trials often use it as the active comparator because it is the established single-agonist standard. This guide covers the molecule, the STEP and SUSTAIN results, injectable versus oral forms, and how research-grade Semaglutide sits on the New-U catalogue. For the Ozempic question, see Is Ozempic a Peptide?. For single-versus-dual comparison, see Semaglutide vs Tirzepatide.

Plain-English summary. Semaglutide is an approved medicine in the United States, the United Kingdom and many other jurisdictions when supplied through licensed channels as Ozempic, Wegovy or Rybelsus. Research-grade semaglutide, sold as a lyophilised reference peptide for laboratory use, is a separate non-medicine category. New-U sells only the research reagent, not the medicine, with no human-use claims, no dosing guidance and no therapeutic protocol. This page is general information, not legal or medical advice.

What semaglutide actually is

Semaglutide is a 31-amino-acid analogue of human glucagon-like peptide-1 (GLP-1). It uses the GLP-1(7–37) backbone with three engineering changes: an Aib substitution at position 8 to block DPP-4 cleavage, an arginine at position 34 , and a C18 fatty di-acid on Lys26 via a γ-Glu-2xOEG linker. The fatty di-acid drives reversible albumin binding. That binding extends half-life from native GLP-1’s ~2 minutes to semaglutide’s ~7 days.

The result is a selective GLP-1 receptor agonist with no off-target GIP or glucagon activity. Pharmacokinetics support once-weekly subcutaneous dosing in the licensed setting. The full mechanism is reviewed in the StatPearls semaglutide chapter.

Mechanism of action, in plain English

GLP-1 receptor agonism produces a cluster of overlapping effects:

Slowed gastric emptying. Food residence time in the stomach increases, prolonging satiety signalling.

Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce drive to eat and the hedonic reward signal from food.

Glucose-dependent insulin secretion. β-cell response to a glucose load is amplified only when glucose is elevated. That is why GLP-1 agonists do not cause hypoglycaemia the way insulin or sulfonylureas can.

Glucagon suppression in a glucose-dependent manner, lowering hepatic glucose production.

What semaglutide does not do, in contrast to tirzepatide and retatrutide, is activate the GIP or glucagon receptors. That is the single mechanistic line separating it from the dual and triple agonists.

The clinical evidence: STEP, SUSTAIN and SELECT

Semaglutide has the deepest Phase 3 evidence base of any peptide in the incretin class:

SUSTAIN (type-2 diabetes, 10 trials). Reported HbA1c reductions of ~1.5–1.8% from baseline at the 1.0 mg weekly dose, superior to comparators across the programme including sitagliptin (SUSTAIN-2), exenatide (SUSTAIN-3) and insulin glargine (SUSTAIN-4).

STEP (chronic weight management, 8 trials). STEP-1 (NEJM, 2021) reported mean body-weight reduction of ~14.9% over 68 weeks at the 2.4 mg dose in adults with obesity without diabetes, vs ~2.4% for placebo. The 2.4 mg dose became the basis for the Wegovy approval.

SELECT (cardiovascular outcomes). It showed a significant reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease. It was the first GLP-1 outcomes trial in a non-diabetic population, and it underpinned the 2024 cardiovascular-protection label expansion.

Injectable vs oral semaglutide

Semaglutide is the only GLP-1 agonist with an approved oral formulation (Rybelsus). The molecule is the same; the formulation differs. Rybelsus co-formulates semaglutide with SNAC (sodium N-(8-(2-hydroxybenzoyl) amino) caprylate). SNAC briefly raises gastric pH and loosens the mucosal barrier so the peptide can cross.

Oral bioavailability is around 0.4–1.0% . That is why labelled oral dose strengths are much higher than injectable ones. Licensed oral labelling also requires specific empty-stomach timing for absorption. Those details belong to the medicine label, not to research-compound handling.

Semaglutide vs tirzepatide vs retatrutide

The full incretin landscape:

Compound Receptor profile Amino acids Half-life Status Semaglutide Semaglutide GLP-1 only 31 ~7 days Approved (Ozempic, Wegovy, Rybelsus) Tirzepatide Tirzepatide GLP-1 + GIP 39 ~5 days Approved (Mounjaro, Zepbound) Retatrutide Retatrutide GLP-1 + GIP + glucagon 39 ~6 days Phase 3, no approval

In the SURMOUNT-5 head-to-head (NEJM, 2025), tirzepatide produced a significantly greater mean reduction in body weight than semaglutide over 72 weeks. Semaglutide remains the more-studied molecule and the only one with a cardiovascular outcomes trial in a non-diabetic obese population.

Semaglutide as a research compound

On the New-U catalogue, the research-grade reference peptide is listed as Semaglutide . It shares the same 31-amino-acid sequence and selective GLP-1 mechanism described above. Here it is supplied as a research compound beside our wider incretin reference range (semaglutide, tirzepatide and retatrutide), not as a licensed medicine.

>99% HPLC purity , independently verified by Janoshik Analytics and Freedom Diagnostics , with a per-batch Certificate of Analysis.

Sealed 10-vial packs , lyophilised, multiple mg/vial tiers.

Tracked worldwide delivery , with flat-rate UK / US / EU options.

No human-use, dosing, therapeutic or weight-loss claims anywhere on the listing.

Operated by a Wyoming-registered distributor - a verifiable legal entity, not an anonymous storefront.

How to verify semaglutide purity

For a 31-amino-acid lipidated peptide, the purity questions are:

HPLC purity >99% by reversed-phase chromatography. Below that band, walk away.

Mass-spec identity match to the calculated monoisotopic mass of the C187H291N45O59 sequence (~4,113 Da). A wrong mass means the molecule is not semaglutide.

Named third-party lab on the CoA - Janoshik Analytics and Freedom Diagnostics are the two most cited in the research-compound supply chain.

Batch number on the CoA matches the vial.

Full walkthrough: How to Read a Certificate of Analysis.

Red flags on semaglutide listings

The semaglutide search surface is one of the most counterfeited in the entire peptide market. Walk away from any listing that:

Markets “Ozempic”, “Wegovy” or “Rybelsus” outside a licensed pharmacy. Those are Novo Nordisk trade names for the licensed medicine, not for research peptide.

Quotes dosing protocols, mg-per-week schedules, titration ladders or weight-loss promises . Those re-characterise the product as an unlicensed medicine.

Has no CoA , or shows a generic stock CoA with no batch number tied to your order.

Sells pre-filled pens or autoinjectors . Lyophilised reference peptide ships dry in a sealed vial. Pre-filled pens are medicine, not research compound.

Quotes a price implausibly far below the rest of the market.

Operates from a Telegram-only channel or a newly registered Shopify with no legal entity in the footer.

Storage & handling of lyophilised semaglutide

Lyophilised semaglutide is typically stored long-term at −20°C. Sealed vials tolerate brief shipping excursions. Warm vials to room temperature before opening to avoid condensation. After reconstitution, store at 2–8°C and protect from light. Use within a research-relevant window based on your stability data. Full reference: How to Store Peptides. For volume maths, use the reconstitution calculator.

Frequently Asked Questions

What is semaglutide? A 31-amino-acid synthetic peptide and a selective GLP-1 receptor agonist developed by Novo Nordisk. Approved as Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral form).

How long is semaglutide’s half-life? Approximately 165 hours (~7 days) for the injectable form, supporting once-weekly dosing. Driven by a C18 fatty di-acid that reversibly binds albumin.

Is oral semaglutide the same molecule as injectable? Yes - Rybelsus is the same semaglutide molecule, co-formulated with the absorption enhancer SNAC to allow gastric uptake. Oral bioavailability is roughly 0.4–1.0%, which is why oral doses are an order of magnitude higher than injectable.

How is semaglutide different from tirzepatide? Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1 + GIP agonist. In SURMOUNT-5 (NEJM, 2025) tirzepatide produced a greater mean weight reduction over 72 weeks.

Is semaglutide a research compound on this site? Yes. New-U catalogues research-grade semaglutide as Semaglutide, lyophilised reference peptide with a per-batch Certificate of Analysis. Sold research use only, not for human consumption.

Primary sources & further reading

New England Journal of Medicine - STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., 2021)

NEJM - SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff et al., 2023)

NIH/NCBI Bookshelf - StatPearls: Semaglutide

U.S. National Library of Medicine - PubMed: semaglutide

ClinicalTrials.gov - semaglutide trial registry

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way. Ozempic, Wegovy and Rybelsus are trade names of Novo Nordisk; New-U sells research-grade reference peptide only, not the licensed medicine.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Research Semaglutide

New-U Research Compounds catalogues semaglutide as Semaglutide - sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Tracked worldwide delivery. Research use only - not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy Semaglutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.